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Abstract
HIV-associated neurocognitive disorders (HAND) continue to be a consequence of HIV-1
infection among clade B-infected individuals. In contrast, the incidence of severe neurological
impairment is lower among clade C-infected patients in regions of Sub-Saharan Africa and India.
Biological aspects such as replication, cytopathicity, inflammatory response, and neurotoxicity
unique to each clade influence neuropathogenicity and ultimately affect the clinical outcome of the
disease. We hypothesize that productive infection by clade C isolates leads to macrophage-
mediated neurotoxicity, although to a lesser extent than clade B isolates. Using a panel of primary
isolates of clades B and C we demonstrated that clade B has higher replication efficiency in
monocyte-derived macrophages (MDM) through reverse transcriptase activity assay and HIV-1
p24 antigen ELISA. To test the neurotoxicity of clades B and C, we used an in vitro neurotoxicity
model. Conditioned medium from clade B-infected MDM was neurotoxic to rat and human
neuron cultures. In contrast, clade C isolates mediated neurotoxicity when a higher initial viral
titer was used for MDM infection. Furthermore, neurotoxicity mediated by isolates of both clades
correlated with virus replication in MDM. Together, these results suggest that in comparison to
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clade B, primary isolates of clade C have slower replication kinetics in primary MDM, leading to
lower levels of macrophage-mediated neurotoxicity. Elucidating the differences in replication and
macrophage-mediated neurotoxicity between isolates of HIV-1 clades B and C will provide
important insights needed to clarify the disparity seen in HAND incidence.
Keywords
HIV-1 clade B; HIV-1 clade C; Neurotoxicity; Macrophages; HIV-associated neurocognitive
disorders
Introduction
HIV-1-associated neurocognitive disorders (HAND) continue to be of significant clinical
consequence among HIV-1-infected individuals. HAND includes asymptomatic
neurocognitive impairment, mild neurocognitive disorder (MND), and the most severe
manifestation, HIV-1-associated dementia—HAD (reviewed by Boisse et al. 2008).
Following the introduction of antiretroviral therapy, 11% of HIV-1 clade B-infected
individuals develop HAD (Kolson and Gonzalez-Scarano 2000), which is characterized by
motor, behavioral, and cognitive dysfunction. However, neuropsychological profiling using
the International Dementia Scale, a standardized test, found lower incidences of HAD in
developing regions (~1–2% in India) where clade C predominates (Clifford et al. 2007;
Riedel et al. 2006). Less severe forms of neurological impairment, such as MND, have
become more prevalent among HIV-sero-positive individuals in developed countries. Cross-
sectional studies of infected individuals in India reported a 56–60% prevalence of mild
cognitive deficits, not qualifying as motor/cognitive impairment or dementia (Gupta et al.
2007; Yepthomi et al. 2006). The mechanisms underlying the disparity between HIV-1
clades B and C, in regard to HAND severity, are unclear.
HIV-infected macrophages enter the central nervous system, mediating neuronal injury and
dysfunction through the secretion of viral proteins, inflammatory factors, excess glutamate,
and other neurotoxins (Jiang et al. 2001; Zheng and Gendelman 1997). Low incidence of
severe neurological manifestations in clade C-infected individuals does not correlate with
the preferential tropism for CCR5 (Abebe et al. 1999; Zhang et al. 2006). HIV-infected
macrophages drive the pathogenesis of HAND; thus, preferential usage of CCR5 coreceptor
by clade C would presumably cause a higher rather than lower incidence of severe
neurological deficits. Neuropathological studies in India revealed the presence of HIV-1-
infected macrophages in post mortem brains, but an absence of multinucleated giant cells
(MNGC) and multifocal microglial nodules, both of which are frequently found in clade B-
infected patients (Mahadevan et al. 2007). Pro-inflammatory molecules and markers known
to be increased among clade B-infected individuals, such as interleukin (IL)-1α, IL-6, tumor
necrosis factor-α (TNF-α), β2-microglobulin, and neopterin have been identified in the
serum and plasma of clade C-infected individuals from India and Ethiopia (Ayehunie et al.
1993; Kamat et al. 2009). Additionally, clade C viral proteins, such as Tat, exhibit distinct
clade-specific modulation of neuropathogenic molecules from their clade B counterparts
(Campbell et al. 2007; Li et al. 2008; Mishra et al. 2008). Biological aspects unique to each
clade, including genetic diversity of viral proteins, viral replication capacity, cytopathicity,
inflammatory response, and neurotoxicity may all contribute to different neuropathogenic
properties and ultimately affect the clinical outcome of the neurological disease.
Clade C, the most commonly transmitted subtype, accounts for more than 50% of HIV-1
infections world-wide. However, the majority of HIV-1 research focuses on infection
models using clade B strains. We undertook this study to describe the replication efficiency
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and neurotoxicity of a panel of primary isolates of clades B and C using established in vitro
models of human monocyte-derived macrophages (MDM) and primary rat cortical neurons
(RCN). We found that clade B primary isolates have higher replication efficiency in MDM
than clade C isolates. Productive infection by clade B isolates was associated with increased
neurotoxicity. Clade C-mediated neurotoxicity was observed when a higher initial viral titer
was used for MDM infection. The observed neurotoxicity mediated by isolates of both
clades correlated with virus replication in MDM. Our findings show that in comparison to
clade B, primary isolates of clade C studied here have lower replication efficiency in
primary MDM, leading to lower levels of macrophage-mediated neurotoxicity.
Materials and Methods
Isolation and Culture of Primary MDM, RCN, and Human Neurons
Human monocytes were isolated from peripheral blood mononuclear cells (PBMCs) of
HIV-1, -2, and hepatitis B seronegative donors after leukopheresis, and counter-current
centrifugal elutriation (Gendelman et al. 1988). Primary monocytes were cultured as
adherent monolayers at a density of 1.1 × 106 cells/well in 24-well plates and differentiated
for 7 days in Dulbecco’s modified Eagle’s medium (DMEM, GIBCO Invitrogen Corp.,
Carlsbad, CA) supplemented with 10% heat-inactivated pooled human serum (Cambrex Bio
Science, Walkersville, MD), 50 μg/ml gentamicin (GIBCO Invitrogen Corp.), 10 μg/ml
ciprofloxacin (Fisher Scientific, Dubuque, IA), and 1,000 U/ml highly purified recombinant
human macrophage-colony stimulating factor (M-CSF, a generous gift from Wyeth
Pharmaceutical, Cambridge, MA). PBMCs were cultured in RPMI-1640 (GIBCO Invitrogen
Corp.) supplemented with 10% heat-inactivated fetal bovine serum (Invitrogen), 10 IU/ml
IL-2 (R&D Systems, Minneapolis, MN), and 5 μg/ml penicillin–streptomycin (GIBCO,
Invitrogen, Corp.). Primary cortical neurons were prepared from cortices of embryonic day
17–18 (E17-18) Sasco Sprague–Dawley rat fetuses as previously described (Zheng et al.
2001). Briefly, the cortex was dissected and individual cells were mechanically dissociated
in Neurobasal™ medium (Invitrogen Corp.) and differentiated in Neurobasal™ medium
containing B27 supplement (GIBCO Invitrogen Corp.), 0.5 mM glutamine (Sigma–Aldrich),
and 25 μg/ml penicillin–streptomycin. For neurotoxicity assays, neurons were plated onto
poly-D-lysine-coated 96-well plates at a density of 5 × 104 cells/well. Cultured neurons were
assumed to be mature 7–12 days after plating. All experiments were reviewed and approved
by the Institutional Animal Care and Use Committee of the University of Nebraska Medical
Center. Human fetal brain tissue (gestational age 13–16 weeks) was obtained from elective
abortions in full compliance with the University of Nebraska Medical Center (UNMC) and
NIH ethical guidelines. Human neuronal cultures were prepared as previously described
(Zheng et al. 1999). Human neurons were plated on poly-D-lysine-coated 15-mm coverslips
in 24-well plates at a density of 2 × 105 cells/well. Cells were cultured in neurobasal media
supplemented with 1% B27, 1% penicillin/streptomycin, and 0.5 mM glutamine. Ten days
after culture, neurons were deemed mature.
Titration of HIV-1 Isolates, MDM Infection and Collection of MDM-Conditioned Medium
(MCM)
HIV-1JR-FL was obtained from the AIDS Research and Reference Reagents Program at the
NIH National Institute of Allergy and Infectious Diseases (Koyanagi et al. 1987). HIV-1ADA
was isolated from the PBMCs of an infected patient with Kaposi’s sarcoma (Gendelman et
al. 1988). Clade B primary viruses (D02-2562 BG, A00-086 CPx, D02-2562 Sp, and G0048
CPx) were isolated from the spleen (Sp), basal ganglia (BG), or choroid plexus (CPx) in the
trigone of the lateral ventricle of infected patients with HIV Encephalitis (HIVE) (Burkala et
al. 2005). Clade C primary isolates (2873M, 2669M, 1084M, and 1157I) were isolated from
PBMCs of HIV-1-infected mother and infant pairs in Africa (Zhang et al. 2005, 2006). All
Constantino et al. Page 3
Neurotox Res. Author manuscript; available in PMC 2012 October 01.
N
IH
-PA Author M
anuscript
N
IH
-PA Author M
anuscript
N
IH
-PA Author M
anuscript
HIV-1 isolates (listed in Table 1) use CCR5 as a co-receptor (Burkala et al. 2005;
Gendelman et al. 1988; Koyanagi et al. 1987; Zhang et al. 2005, 2006). Primary viruses
were cultured in phytohemagglutinin (PHA, 5 μg/ml, Sigma–Aldrich) stimulated PBMCs
for 14 days before titration. Stock viruses were screened for mycoplasma and endotoxin
using hybridization and Limulus amebocyte lysate assays, respectively. The 50% tissue
culture infective dose (TCID50) of each viral stock was determined by monitoring infection
of TZM-bl cells obtained through NIH AIDS Research and Reference Reagent Program as
described previously (Derdeyn et al. 2000; Marozsan et al. 2004; Platt et al. 1998; Wei et al.
2002). The stock viral titers of each isolate are listed in Table 1. Seven days after plating,
MDM were infected with the aforementioned viral isolates using TCID50/ml indicated in
Table 1. On the second day after infection, medium was removed and substituted with
MDM culture medium (DMEM with 10% heat-inactivated pooled human serum, 50 μg/ml
gentamicin, and 10 μg/ml ciprofloxacin) (Gendelman et al. 1988). On 4, 7, 14, or 21 days
after infection, cells were changed to 0.5 ml/well fresh serum-free Neurobasal™ medium
supplemented with 25 ug/ml penicillin–streptomycin and 5 mM glutamine for 24 h. Culture
supernatants were collected as MCM and subsequently stored at −80°C.
Monitoring of Viral Replication and Cytopathicity
HIV-1 reverse transcriptase (RT) activity was determined from triplicate samples of cell
culture supernatants as previously described (Koenig et al. 1986). Briefly, 10 μl of
supernatant was incubated in a reaction mixture of 0.05% Nonidet P-40, 10 μg of poly(A)/
ml, 0.25 μg of oligo(dT)/ml, 5 mM dithiothreitol, 150 mM KCl, 15 mM MgCl2, and
[3H]TTP in Tris–HCl buffer (pH 7.9) for 24 h at 37°C. Radiolabeled nucleotides were
precipitated with cold 10% trichloroacetic acid on filter paper plates in an automatic cell
harvester and washed with 95% ethanol. Radioactivity was estimated by liquid scintillation
spectroscopy. HIV-1 p24 antigen levels were determined in culture supernatants by enzyme-
linked immunosorbent assay—ELISA (Beckman Coulter, Miami, FL) according to the
manufacturer’s instructions.
The efficiency of infection was analyzed after 14 and 21 days using flow cytometry (FACS
Caliber, BD Biosciences) by evaluating the number of p24-expressing cells. Following
culture in 50 ml Teflon flasks, cells were washed with Flow Cytometry Stain Buffer (BD
Pharmingen, BD Biosciences) and incubated at room temperature in the dark for 30 min
with APC mouse antihuman CD14-conjugated antibody or APC mouse IgG isotype control
(BD Pharmingen). Cells were washed with stain buffer and fixed in the dark at room
temperature for 20 min using fixation buffer (eBiosciences, San Diego, California). Cells
were then washed twice using permeabilization buffer (eBiosciences) and incubated at room
temperature for 20 min in the dark with HIV-1 p24 FITC-conjugated antibody (Santa Cruz
Biotechnology) or FITC mouse IgG isotype control (BD Pharmingen). Cells were washed
twice and resuspended in stain buffer, and HIV-1 p24 cells were then determined by flow
cytometry and analyzed with BD CellQuest Software. At least 10,000 cells were analyzed
per sample. HIV-1 p24-positive cells were also detected by immunocytochemistry. Human
MDM were plated on 15-mm cover slips in 24-well plates and fixed with 4%
paraformaldehyde at room temperature for 20 min after 7, 14, or 21 days of infection. Fixed
cells were blocked with 3% BSA in PBS and incubated at 4°C overnight with primary
antibodies to HIV-1 p24 (monoclonal mouse, DAKO Corp, Carpinteria, CA). Cultures were
washed and incubated for 1 h at room temperature with fluorophore-labeled secondary
antibody Alexa Fluor 488 goat antimouse IgG (Molecular Probes, Eugene, OR). Cover slips
were then mounted on glass slides with VECTASHIELD Hard Set Mounting Medium with
DAPI (VECTOR Laboratories, Inc, Burlingame, CA). Double immunostaining with CD68
and p24 and morphological changes were visualized with a Nikon Eclipse E800 fluorescent
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microscope equipped with a digital imaging program. Photographs have a magnification of
×200.
MAP-2 ELISAs
MAP-2 neuronal antigen was determined in RCN treated with MCM using colorimetric
ELISA as described previously (Zheng et al. 2001). Briefly, fixed RCN were blocked with
3% normal goat serum in PBS and incubated for 1 h with antibodies against MAP-2
(monoclonal mouse, Millipore-Chemicon International, Billerica, MA), followed by
antimouse biotinylated antibody (VECTOR Laboratories) for 30 min. Avidin/biotin complex
solution (VECTOR Laboratories) was added for 30 min, then color was developed using
TMB substrate (Sigma–Aldrich) and terminated with 1 M H2SO4 (Sigma–Aldrich). The
absorbance was read at 450 nm using a microplate reader (Bio-Rad Laboratories, Hercules,
CA). About 50 μM glutamate (Sigma–Aldrich) was used as a positive neurotoxicity control.
MTT Reduction Assay
Cell viability of MDM and RCN was assessed by MTT reduction as described previously
(Jiang et al. 2001; Zhao et al. 2004). Briefly, cells were incubated with 10% MTT (Sigma–
Aldrich) solution in Neurobasal media for 30 min at 37°C. The extent of MTT conversion to
formazan by mitochondrial dehydrogenase, indicating cell viability, was determined by
measuring absorbance at 490 nm using a microplate reader (Bio-Rad Laboratories). About
50 μM glutamate (Sigma–Aldrich) and the NMDA receptor antagonist MK801 (Invitrogen
Co., Carlsbad, CA) alone and in combination were used as controls.
In Situ TUNEL Assay
Terminal deoxynucleotidyl transferase dUTP nick end labeling (TUNEL) was used to
determine apoptosis of human neurons treated with 25% MCM. About 3 days after
treatment, apoptotic neurons were detected using the In Situ Cell Death Detection kit
(Roche, Manheim, Germany), following the manufacturer’s instructions. Results are
expressed as a percentage of TUNEL-positive cells over the total amount of neurons (nuclei
stained by DAPI). Random images were acquired from immunostained fields using a Nikon
Eclipse E800 microscope. A minimum of ten fields in duplicate wells was counted for each
treatment condition and photographs have a magnification of ×200.
Statistical Analyses
The data were evaluated statistically by the analysis of variance (ANOVA), followed by a
Bonferroni posttest or Tukey’s test for multiple comparisons. Data were analyzed as ±
standard error of the mean (SEM), and significance was determined as p < 0.05. Spearman’s
correlation was used to examine associations. To account for any donor-specific differences,
all experiments were performed in triplicate from at least three donors.
Results
Replication Differences in MDM Among a Panel of Primary HIV-1 Isolates
Investigations on HIV-1 infection in MDM using primary clade C isolates have been sparse.
We obtained a panel of CCR5-tropic HIV-1 primary isolates, which included four clade B
isolates D02-2562 BG, A00-086 CPx, A00-275 Sp, and G0048 CPx and four clade C
isolates 2873M, 2669M, 1084I, and 1157I (Table 1). All primary isolates were initially
cultured and expanded in PBMCs. Viral replication in PBMCs was monitored by measuring
RT activity at 3, 5, 10, and 14 days postinfection (Supplemental Fig. 1). Isolates from both
clades generated a comparable exponential increase of RT activity in the culture medium.
Intraclade differences were evident as isolate D02-2562 Sp (clade B) had higher RT activity
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than all other isolates. Similarly, clade C isolates 1084I and 1157I had lower RT activity at
all time points. The primary isolates were titrated in TZM-bl cells and comparable titers
were found (Table 1). To characterize the infection course in primary human MDM, two
clade B laboratory-adapted strains (HIV-1ADA and HIV-1JR-FL) were used as infection
controls, whereas uninfected MDM were used as negative controls in each experiment. We
compared the replication kinetics of viral isolates by performing parallel infections in MDM
with equivalent titers (400 TCID50/ml) and measured the HIV-1 RT activity at different time
points during the infection course. Primary isolates of clade B generated an exponential
increase of virus in the medium and reached a maximum, comparable to laboratory-adapted
strains, at 7 and 14 days postinfection (Fig. 1a and b). The clade C isolates exhibited a
delayed increase in replication, as measured by RT activity, and reached a peak
approximately 21 days postinfection (Fig. 1c). Through 14 days of infection, RT activity of
clade C isolates in the culture medium was higher than the uninfected control, but
significantly lower than day-matched clade B culture medium (p < 0.001). Replication
capacity of clade B and C isolates was comparable (p > 0.05) at 21 days postinfection.
However, RT activity of clade C isolates at 21 days postinfection was lower than clade B RT
activity at 14 days postinfection (p < 0.001). RT activity at 28 days postinfection revealed
clade C isolates, with the exception of 2669M, reached maximum replication at 21 days
postinfection (data not shown). Maintenance of MDM cultures beyond 21 days becomes
difficult because of the cell death that results from extensive periods of in vitro culture.
To further characterize the infection course, we measured HIV-1 p24 antigen levels in cell
culture supernatants using ELISA. Consistent with the RT activity, p24 production for
laboratory-adapted strains (Fig. 1d) and for clade B primary isolates (Fig. 1e) peaked from 7
to 14 days postinfection. In contrast, p24 levels in clade C-infected cultures revealed a
maximum average production 21 days postinfection (Fig. 1f). Taken together, these
experiments suggest the four HIV-1 clade C primary isolates studied here, in comparison to
clade B, replicate with delayed kinetics leading to a less robust infection in primary MDM.
Limited Cytopathicity in MDM Infected by Clade C Isolates
We have previously reported that productive infection by HIV-1 laboratory-adapted strains
induces cell death (Cui et al. 2008). To determine the extent of cytopathicity induced by
HIV-1 primary isolates, we infected MDM with 400 TCID50/ml of each of the viral isolates
(Table 1) and evaluated MDM viability by MTT reduction assay at 4, 7, 14, and 21 days
postinfection. The viability of infected MDM cultures was compared with day-matched
uninfected MDM. Consistent with previous findings from our laboratory, productive
infection with laboratory-adapted strains significantly reduced MDM viability at 14 and 21
days postinfection (Fig. 2a). Similarly, infection by clade B primary isolates significantly
decreased cellular viability by 14 days postinfection (Fig. 2b). On the contrary, clade C-
infected MDM retained higher viability than clade B throughout a period of 21 days (Fig.
2c). These findings confirm that clade B primary isolates exhibit higher levels of
cytopathicity when compared with the clade C primary isolates under study.
Neurotoxicity Mediated by MDM Infection With Clade B Isolates, but Not Clade C
Both HIV-1-infected and immune-activated macrophages secrete viral proteins,
inflammatory factors, glutamate, and other molecules that contribute to neurotoxicity,
causing neuronal injury, dysfunction, and death (Kaul et al. 2005). We evaluated indirect
macrophage-mediated neurotoxicity through a well-defined RCN culture system. MCM
from MDM cultures infected at 400 TCID50/ml was added to RCNs and cell viability was
determined by MTT assay. Glutamate treatment significantly reduced RCN viability and
was used as a positive control for neurotoxicity (data not shown). MCM, collected 14 and 21
days postinfection with clade B isolates, significantly reduced RCN viability (Fig. 3a and b,
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gray bars). In contrast, treatment with MCM collected at 14 and 21 days postinfection from
clade C-infected cultures did not significantly reduce RCN viability (Fig. 3, closed bars).
The data suggest conditioned medium from MDM infected with equal initial viral titers of
clade B isolates, but not the four clade C isolates used, mediate significant indirect
neurotoxicity in RCNs.
Increase in Replication Capacity for Clade C Isolate 2669M
As it has been suggested that differences in macrophage-mediated neurotoxicity between
primary isolates of clades B and C may be attributable to unequal levels of viral replication
in MDM, we performed parallel infections of MDM with increasing viral titers for clade C
isolates. We measured RT activity at days 7, 14, and 21 to monitor the progress of infection
and to identify which viral titers produced comparable replication levels between isolates of
both clades (data not shown). Viral replication, as measured by RT activity, was comparable
in cultures infected by 200 TCID50/ml of D02-2562 (clade B) and 800 TCID50/ml of 2669M
(clade C) (Fig. 4a). In parallel with viral replication assessment, we evaluated the cellular
viability of infected MDM (Fig. 4b). Cellular viability was significantly decreased at 14 and
21 days following infection with D02-2562. The reduction in MDM viability was consistent
with the decrease in viability observed following infection with 400 TCID50/ml of clade B
isolates (Fig. 2). MDM infected with 800 TCID50/ml of 2669M remained viable throughout
the course of infection.
To directly compare the infection course in MDM, we analyzed the amount of HIV-1 p24-
positive cells in the infected cultures. At 14 and 21 days postinfection, FACS analysis
revealed that the number of MDM infected by clade C isolate 2669M was minimal
compared to isolate D02-2562 BG (Fig. 4c). In cultures infected by D02-2562 BG, 38 and
87% of MDM were p24-positive by 14 and 21 days postinfection, respectively (Fig. 4d).
The number of p24-positive MDM in 2669M cultures increased as infection progressed over
time, as typically 5% of the MDM were p24-positive and the amount continued to increase
to 32% by 21 days postinfection. These findings were corroborated by manual quantification
of p24-positive MDMs using immunostaining, where isolate D02-2562 BG infected a
significantly higher number of cells (Fig. 4e). Additionally, MDM cultures were observed
for MNGC formation using HIV-1 p24 antigen and nuclear DAPI staining (Supplemental
Fig. 2). MNGCs are formed by the fusion of macrophages and are a characteristic
histopathologic feature of HIV-associated neuropathologies (Boisse et al. 2008; Navia et al.
1986). By day 21 postinfection, approximately 60% of cells in D02-2562BG-infected
cultures were MNGCs. Although infection with 2669M (clade C) revealed p24-positive
cells, MNGC formation was not evident (0% of infected cells were MNGCs) throughout the
course of infection. Because a small number MDM are infected by 2669M-clade C isolate,
these findings offer a possible explanation for the observation of negligible neurotoxicity.
Productive Infection Leads to Neurotoxicity
We assessed the indirect neurotoxic effects of HIV infection on RCN and found that
neuronal viability was significantly reduced following treatment of RCN with MCM
collected at 7, 14, and 21 days postinfection with 200 TCID50/ml of D02-2562 (Fig. 5a).
Similar to previous results (Fig. 3), treatment with MCM collected at 7 and 14 days from
cultures infected with 2669M had no significant effect on RCN, as viability was comparable
to cultures treated with MCM from uninfected MDM. In contrast, treatment with MCM
collected at 21 days from 2669M-infected cultures had a significant impact on RCN viability
(Fig. 5a). MAP-2 ELISAs were used to quantify the extent of the damage in RCN following
a 3-day treatment with conditioned medium from infected MDM cultures (Fig. 5b). MAP-2
is found on neuronal dendrites and cell body; thus, loss of MAP-2 immunoreactivity is more
sensitive for determining the extent of neuronal injury and demise. MCM collected from
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D02-2562-infected cultures for 21 days caused more than 20% reduction of MAP-2 in
treated RCN when compared to MCM from uninfected controls. Similarly, MCM collected
21 days after 2669M infection decreased neuronal MAP-2 expression, albeit this reduction
was closer to 10–15%. The data suggest conditioned medium from MDM, infected by clade
B or C primary isolates, causes neuronal damage. Additionally, viral replication as
determined by RT activity in the culture medium correlates with macrophage-mediated
indirect neurotoxicity (Fig. 5c), suggesting that at high levels of productive infection, HIV
isolates may induce neurotoxicity of RCN.
To test whether conditioned medium also had neurotoxic effects on human neurons, cultures
were treated for 3 days with MCM collected at 7, 14, and 21 days postinfection with a clade
B or C isolate, and cell death was determined using TUNEL assays. Apoptosis induced by
MCM from infected macrophages was evident, as cultures had visible nuclear condensation
and cell shrinkage (Fig. 6a). Quantification of TUNEL assays showed treatment with
D02-2562 MCM caused more apoptosis than treatment with 2669M MCM (Fig. 6b). Taken
together, these results suggested that increased viral replication by primary isolates of clades
B and C leads to neurotoxicity, with clade B primary isolates being the most neurotoxic to
both rat and human neurons.
Discussion
HIV-1 clade B-infected macrophages drive the pathogenesis of HAND seen in infected
individuals. The low incidence of severe neurological manifestations associated with HIV-1
clade C infection does not correlate with the preferential CCR5 tropism of clade C viruses.
In this study, we have characterized the replication efficiency and macrophage-mediated
neurotoxicity of a panel of eight primary isolates from HIV-1 clades B and C. When
performing parallel infections of MDM using similar initial viral titers, clade B primary
isolates replicated more efficiently. Viral replication of all four clade C isolates in MDM
was slow in comparison to clade B isolates. However, by increasing the viral titer of clade C
isolates, we were able to obtain replication levels comparable to clade B. MDM infected
with clade B isolates had lower viability than cells infected with clade C isolates, even when
a lower initial viral titer was used for infection. Conditioned medium, obtained from MDM
infected with clade B primary isolates, displayed neurotoxic properties. MCM from
macrophages infected with clade C isolates induced neurotoxicity when higher initial viral
titers were used to achieve a productive infection, as determined by replication capacity (RT
activity). Lower levels of neurotoxicity by clade C isolates in this report are likely the result
of an efficient, albeit slow in vitro viral replication in MDM.
Recently, understanding the effects of HIV-1 clade diversity on the induction of
neuropathological disorders has obtained great interest. Neuropsychological testing revealed
a lower incidence of severe neurological impairment, such as HAD in regions where clade C
predominates (Clifford et al. 2007; Riedel et al. 2006). Interclade differences in
macrophage-mediated neurotoxicity may account for the observed discrepancies in
neurological dysfunction between HIV-1 clades B and C. Our results demonstrate that in
vitro replication of clade C isolates in primary human MDM is delayed compared to clade B
isolates. The replication kinetics of clade C primary isolates used in this investigation
(Zhang et al. 2006) and their cloned proviruses (Zhang et al. 2010) has been studied
previously along with NL4-3, a laboratory-adapted virus. For this investigation, we wanted
to compare a panel of primary isolates using the same TCID50/ml to reflect the difference in
replication efficiency in MDM. We then adjusted the macrophage infection by using 200
TCID50/ml for clade B isolate D02-2562 and 800 TCID50/ml for clade C isolate 2669M to
achieve similar levels of viral replication (Figs. 4-6).
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Clade C primary isolates have equal transmission fitness but reduced pathogenic fitness
relative to other group M HIV-1 isolates (Abraha et al. 2009). Additionally, clade C R5
viruses exhibit slower replication profiles on CD4+ lymphocytes in comparison to clade B
viruses, whereas clade C X4 viruses replicated with comparable efficiency to clade B X4
viruses (Pollakis et al. 2004). Nevertheless, delayed replication kinetics of clade C isolates
in MDM cultures does not imply that poor replication is expected in vivo or in other cell
populations. Increased in vitro fitness of clade B over clade C has been previously observed
in human PBMCs, CD4+ T cells, and blood-derived macrophages, but not in skin-derived
Langerhans cells (Ball et al. 2003). However, the cytokine network of the gut-associated
lymphoid tissue supports HIV-1 clade C viral replication via preferential activation of the
clade C promoter (Centlivre et al. 2006). Accordingly, replication kinetics and infection
progress of clade C isolates may be affected or even restricted by delayed viral entry,
reverse transcription, integration to the host-cell genome, or induction of the viral promoter.
It is well known that clade C is preferentially a CCR5-tropic virus with an in vitro
nonsyncytium-inducing (NSI) phenotype (Abebe et al. 1999; Thompson et al. 2002). The
NSI phenotype is traditionally evaluated in vitro by observing syncytia formation in MT-2 T
lymphoblasts. Within the brain, mononuclear phagocyte-derived MNGCs occur as a
response to viral infection and are considered a hallmark of severe HIV-1 clade B-associated
neuropathology. We previously demonstrated that productive HIV-1ADA infection induces
the formation of MNGCs and decreases cellular viability via apoptosis in MDM cultures
(Cui et al. 2008; Huang et al. 2006). Although clade C-infected macrophages are found in
HIV-infected brain tissue during autopsy, MNGC are absent (Mahadevan et al. 2007). Our
current results reinforce these findings by demonstrating a lack of MNGC formation in
primary MDM cultures infected with primary clade C isolates. Furthermore, this outcome
provides evidence of remarkable macrophage cytopathicity, including formation of MNGC
and cell death in MDM infection with clade B, but not with clade C isolates.
To the best of our knowledge, this is the first report comparing neurotoxicity of RCN and
human neurons mediated by primary human macrophages infected by primary isolates of
HIV-1 clades B and C. This approach allowed us to obtain physiologically relevant results
regarding effects on infection progression in MDM and resulting neuronal toxicity. Previous
studies have compared the in vitro neurotoxicity of HIV viral proteins and demonstrated that
clade C Tat has an attenuated phenotype that renders it less neurotoxic than its clade B
counterpart (Campbell et al. 2007; Li et al. 2008; Mishra et al. 2008). Diminished clade C
neuropathogenesis has been confirmed in vivo using infectious molecular clones of clades B
(HIV-1ADA) and C (HIV-1Indie-C1) in the HIVE SCID mouse model (Rao et al. 2008). These
in vivo studies demonstrated that exposure to clade C resulted in mild and not severe
cognitive dysfunction, whereas mice exposed to HIV-1ADA exhibited increased astrogliosis
and neuronal loss. Moreover, commonly used laboratory-adapted strains are cultured in vitro
through multiple rounds of infection and may not be representative of primary isolates.
Replication efficiency increases over time in culture and possibly creates a more infectious
strain of HIV than primary isolates (Lawson et al. 2002; Simon et al. 2003). Indeed,
HIV-1ADA exhibited faster and higher infection efficiency than the primary isolates in our
macrophage system. Hence, this investigation is unique in that we infected primary MDM
and assessed neurotoxicity using primary isolates that had similar culturing history and were
obtained from infected individuals in the USA and Africa.
A possible limitation to our study is that we used clade C blood isolates that may have a
skewed pathogenic potential to a less neurotoxic phenotype when compared to clade B brain
isolates. Brain-derived viruses are more neurotoxic than blood isolates, potentially the result
of variations in the viral envelope (Power et al. 1998). The gp120 variant Asn 283 (N283) is
more frequent in isolates from brain tissues of HAD patients, such as HIV-1ADA, compared
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to isolates from lymphoid and non-HAD brain tissues (Dunfee et al. 2006). N283 enhances
macrophage tropism by enhancing viral fusion and entry when low levels of CD4 are
expressed. Notably, we analyzed 528 clade C envelope sequences from the Los Alamos HIV
Sequence Database and found that only one isolate, 05ZAFV7, (GenBank: DQ382365;
Michler et al. 2008) contained N283. Clade C isolates used in this investigation lack the
N283 mutation and may be at a disadvantage for replication in macrophages by having a
limited capacity to use low-CD4 expression levels. However, it is important to note that
clade C isolates in this study mediated neurotoxicity at high viral titers in our MDM culture
system; suggesting neurotoxicity is a possible result of increased viral replication. Certainly,
it would be interesting to assess the neurotoxicity of clade C brain isolates when they
become available.
In conclusion, clade C isolates investigated herein possess slow replication kinetics in MDM
and induce neurotoxicity at high viral replication levels. These clade C isolates have a
neurotoxic potential that may be of consequence if viral infection progresses and
immunosuppression is established. Multiple factors, including host and viral genetic factors,
clinical characteristics, and opportunistic infections, may provide the environment for
development of milder forms of HAND. As a consequence, it is possible that clade C-
infected patients may be at risk of developing more severe cognitive impairment as disease
progresses and more infected macrophages infiltrate the brain. Future studies on the
mechanisms leading to variations of replication in macrophages and subsequent
inflammatory responses among isolates of clades B and C and the relationship between these
pathways and differences in neurovirulence can clarify the disparity of HAND incidence.
Supplementary Material
Refer to Web version on PubMed Central for supplementary material.
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Fig. 1.
Viral replication of HIV-1 clade B and C isolates in human MDM. Macrophage cultures
were infected with 400 TCID50/ml of HIV-1 laboratory-adapted strains, clade B, or clade C
primary isolates. Supernatants were collected at days 4, 7, 14, and 21 postinfection. Viral
replication was monitored through RT activity (a–c) and p24 antigen production (d–f).
Values represent SEM from three independent experiments
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Fig. 2.
Cellular viability of macrophages infected by clade B or C isolates. MDM cultures were
infected with 400 TCID50/ml of HIV-1 laboratory-adapted strains (a), clade B (b), or clade
C (c) isolates. Supernatants were collected at 4, 7, 14, and 21 days postinfection (dpi). Cell
viability was determined by MTT reduction assay and results correspond to the percentage
of viable cells normalized to day-matched uninfected control MDM. Values represent SEM
from three independent experiments and * denotes p < 0.01 in comparison to control
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Fig. 3.
Neurotoxicity of HIV-1 clade B or C-infected MDM in RCN. RCN were treated for 4 days
using conditioned media collected at 14 (a) and 21 (b) days after infection by a panel of
HIV-1 laboratory-adapted strains and primary isolates of clades B and C. Cell viability was
determined by MTT assay and neurotoxicity corresponds to the percentage of viable cells
normalized to day-matched uninfected control conditioned media. Values represent SEM
from three independent experiments and * denotes p < 0.01 in comparison to control
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Fig. 4.
Replication capacity of isolates D02-2562 BG (clade B) and 2669M (clade C) following
viral titer adjustment. MDM cultures were infected with 200 TCID50/ml of D02-2562 (clade
B primary isolate) or 800 TCID50/ml 2669M (clade C primary isolate) for 7, 14, and 21
days. Viral replication was monitored in cell culture supernatants through RT activity (a).
MDM viability was determined by MTT reduction assay (b). MTT results correspond to the
percentage of viable cells normalized to day-matched controls. Efficiency of infection was
analyzed after 14 and 21 days postinfection (dpi) using flow cytometry by evaluating the
number of p24-expressing MDM (c). Percentage of p24-positive cells in CD14+ MDM with
mean values shown for independent experiments (n = 6 for 14 dpi and n = 4 for 21 dpi)
using MDM from different donors (d). Quantification of MDM stained with HIV-1 p24 and
presented as percentage of total CD68-positive MDM (e). Values represent SEM from
independent experiments and * denotes p < 0.01 in comparison to control
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Fig. 5.
Assessment of neurotoxicity in RCN following treatment with conditioned medium from
infected cultures. RCN were treated with MCM collected from cultures infected for 7, 14,
and 21 days postinfection (dpi) with 200 TCID50/ml of D02-2562 (clade B primary isolate)
or 800 TCID50/ml 2669M (clade C primary isolate). RCN viability was assessed by MTT
assay (a). MTT results correspond to the percentage of viable cells normalized to day-
matched controls. MAP-2 percentage was determined using ELISA for RCN cultures treated
with clade B or C MCM (b). MAP-2 is expressed as a percentage in comparison to control
MCM. The association between RT activity levels and RCN viability following treatment
with MCM collected at 14 and 21 dpi was determined by Spearman’s correlation (c). Values
represent SEM from three independent experiments and * and ** denote p < 0.05 and p <
0.01, respectively in comparison to control
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Fig. 6.
Apoptosis of human neurons following treatment with conditioned medium from infected
cultures. Human neurons were treated for 3 days with MCM collected from cultures infected
for 7, 14, and 21 days with 200 TCID50/ml of D02-2562 (clade B primary isolate) or 800
TCID50/ml 2669M (clade C primary isolate). Apoptotic cells were labeled with TUNEL,
and nuclei of total cells were stained with DAPI (a). Photographs have a magnification of
×200. Neuronal apoptosis is expressed as a percentage of TUNEL-positive cells over the
total amount of neurons (nuclei staining by DAPI, b). Data values represent SEM and *
denotes p < 0.01 in comparison to control
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Table 1
HIV-1 isolates
HIV-1 isolate Classification Source Reference TCID50/mla
ADA Lab-adapted B PBMCs Gendelman et al. (1988) 6.31 × 104
JR-FL Lab-adapted B Brain Tissue Koyanagi et al. (1987) 2.51 × 104
D02-2562 BG Primary B Basal ganglia Burkala et al. (2005) 2.51 × 104
A00-086 CPx Primary B Choroid plexus Burkala et al. (2005) 1.26 × 104
D02-2562 Sp Primary B Spleen Burkala et al. (2005) 1.58 × 105
G0048 CPx Primary B Choroid plexus Burkala et al. (2005) 1.58 × 105
2873M Primary C PBMCs Zhang et al. (2006) 1.00 × 104
2669M Primary C PBMCs Zhang et al. (2006) 2.00 × 104
1084I Primary C PBMCs Zhang et al. (2006) 1.00 × 105
1157I Primary C PBMCs Zhang et al. (2005) 2.51 × 104
a
TCID50/ml determined by titration in TZM-bl cells as detailed in the Sect. Materials and Methods
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Supplemental Figure 1. Viral replication of HIV-1 clade B and C isolates in human PBMCs. PBMC 
cultures were stimulated with PHA for 48 hours before infection with primary isolates. Following 
infection of clade B or C isolates, PBMC cultures were washed 3 times to remove unbounded virus. 
Supernatants were collected at 3, 5, 10, and 14 days post-infection and viral replication was monitored 
through RT activity assay. 
Supplemental Figure 2. Cytopathicity of macrophages infected by primary isolates of clade B or C. 
MDM were cultured on cover slips for 14 and 21 days with uninfected control media or infected with 
200 TCID50/ml of HIV-1ADA (laboratory-adapted strain), D02-2562 BG (clade B primary isolate), or 800 
TCID50/ml 2669M (clade C primary isolate). Cells were stained with anti-HIV-1 p24 antibodies and nuclei 
were stained with DAPI. Panels are representative of three separate donors. 
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